JNJ Johnson & Johnson

Mentions (100)

• News (RSS)zerohedge·4h ago·Neutral

  The Five-Year Fuel Crisis Why The World Economy Is Paying For A War It Thinks Is Ending The Five-Year Fuel Crisis Why The World Economy Is Paying For A War It Thinks Is Ending Authored by Larry C. Johnson via SonarIntelligence (Sonar21), Once again Karl W. Miller has put numbers to a problem that most of the commentariat still treats as a temporary price spike. His latest forward outlook, "The Five-Year Global Energy Crisis," dated October 3, makes an argument that should alarm every finance min

  View source ↗
• Newszacks.com·13h ago·Positive

  Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note Johnson & Johnson (JNJ) closed at $252.83 in the latest trading session, marking a -1.25% move from the prior day.

  View source ↗
• News (RSS)zerohedge·1d ago·Neutral

  "Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved "Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved Within three months of firing Tracy Beth Høeg, its top drug regulator, the FDA had approved the first mRNA flu shot, cleared a Sanofi diabetes treatment for children that she had held up, and approved a twice-rejected melanoma drug whose ma

  View source ↗
• News (RSS)forbes·2d ago·Neutral

  UFC 335 Announces Huge Alex Pereira Fight And BMF Title Bout UFC 335 is set for Dec. 12 in Las Vegas with Oliveira vs. Lopes for the BMF title, Pereira vs. Pavlovich, Pyfer vs. Nickal and Moreno vs. Johnson.

  View source ↗
• Newsfool.com·3d ago·Neutral

  The Stock Market Just Flashed a Warning Signal Seen Only Twice in 155 Years. Here Are 3 Stocks That Can Weather What History Says Comes Next. These stocks should hold up well no matter what the future holds for the overall market.

  View source ↗
• 4chan /biz/biz·3d ago·Neutral

  … or bear trend, though, some them I just know. Despite that, you can't even imagine all the research that I've done. Here you go. 10 ticker portfolio: >BRK.B 12.5% >JNJ 7.5% >AVGO 15% >CDNS 12.5 >IDCC 12.5 >MA 10% >IDXX 10% >VRSK 7.5% >BMI 7.5% >USLM 5% If you want a more aggressive 6 ticker portfolio. Higher risk for potentially higher reward: >BRK.B 20% >AVGO 25% >IDCC 15% >IDXX 15% >MA 12.5% >BMI 12.5%

  View source ↗
• 4chan /biz/biz·3d ago·Neutral

  I'm dry and itchy and Aveeno (ticker: KVUE, formerly JNJ) isn't doing s***

  View source ↗
• Newszacks.com·3d ago·Neutral

  J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch JNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.

  View source ↗
• Newsprnewswire.com·4d ago·Neutral

  …is and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112 SPRING HOUSE, Pa., Oct. 2, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE® (icotrokinra) on high-impact plaque psoriasis (PsO) sites.

  View source ↗
• News (Marketaux)economictimes.indiatimes.com·4d ago·Positive

  India has biotech talent and know-how, but funding ecosystem lags: Lilly CEO Mounjaro and Zepbound together accounted[+330 characters]

  View source ↗
• News (RSS)thestreet·4d ago·Negative

  BofA thinks Wall Street is underestimating one J&J drug Bank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company's third-quarter earnings.

  View source ↗
• News (RSS)fool·4d ago·Negative

  Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.

  View source ↗
• News (Marketaux)thestockmarketwatch.com·4d ago·Positive

  [DowJonesToday]Dow Jones Remains Resilient Amidst Mixed Q4 Kickoff Healthcare and telecommunications also s[+267 characters]

  View source ↗
• News (RSS)zerohedge·4d ago·Positive

  Jensen, Zuck Gang Up On 'Doomer' Dario Behind Closed Doors At White House AI Summit Jensen, Zuck Gang Up On 'Doomer' Dario Behind Closed Doors At White House AI Summit Tuesday's White House "Super Intelligence" luncheon was sold as a kumbaya moment. Tech titans flanked President Trump on the driveway after signing a voluntary, "morally binding" pledge to police themselves, and the cameras got their picture of a united industry calming the public's nerves. Behind the scenes, it was a different st

  View source ↗
• News247wallst.com·4d ago·Neutral

  JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.

  View source ↗
• News (RSS)marketwatch·4d ago·Neutral

  Why Amazon got a call-up to the Goldman Sachs conviction list of top stocks What’s in the conviction list: Amazon, Huntington, Occidental, Burlington, Johnson Control. What’s out: Tyson, ConocoPhillips, Golar, Loar, Air Products & Chemicals

  View source ↗
• News (RSS)barrons·4d ago·Neutral

  Basic Materials Roundup: Market Talk Find insight on Lynas Rare Earths, Johnson Matthey and more in the latest Market Talks covering Basic Materials.

  View source ↗
• News (RSS)fool·4d ago·Positive

  History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade. Medtronic is following a strategy that has worked well for Johnson & Johnson.

  View source ↗
• News (RSS)fool·5d ago·Positive

  3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High This is not an exhaustive list.

  View source ↗
• Newsfool.com·5d ago·Positive

  3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High Johnson & Johnson has a deep and diversified pharmaceutical portfolio. The company's robotic surgical system, Ottava, could become a meaningful growth driver.

  View source ↗
• News (Marketaux)thestockmarketwatch.com·5d ago·Positive

  [DowJonesToday]Dow Jones Climbs as Industrial and Tech Strength Offsets Retail Slump In the healthcare space, Johnson</em[+293 characters]

  View source ↗
• Newszacks.com·5d ago·Positive

  Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

  View source ↗
• Newsbenzinga.com·6d ago·Neutral

  Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Johnson & Johnson (NYSE:JNJ) will release earnings for its third quarter before the opening bell on Tuesday, Oct. 13.

  View source ↗
• News (RSS)zerohedge·6d ago·Neutral

  Moscow Closes The Door: How Putin & Lavrov Hardened Russia's Line On Ukraine In Ten Days Moscow Closes The Door: How Putin & Lavrov Hardened Russia's Line On Ukraine In Ten Days Authored by Larry C. Johnson via SonarIntelligence (Sonar21), In mid-September, the Kremlin was signaling that negotiations could resume. Putin had said the trilateral talks with the United States and Ukraine would be unlikely before the State Duma elections, but that Russia would be ready to resume contacts after them.

  View source ↗
• PodcastCompound And Friends·6d ago·Neutral

  I just think that if you dig in, it is nuanced. Well, it is, and chart back on. Staples and utilities are not just considered defensive. They're also interest rates sensitive. The primary, a lower of these stocks, at least historically, has been their dividend yields. And so, we talk about higher treasury bond yields representing competition for the stock market. This is the area of the stock market they're competing with. And people who say, should I, I'm making these numbers up. Should I take

  View source ↗
• PodcastCompound And Friends·6d ago·Positive

  Yeah, he's a pop, on top of being a genius and out innovating everyone and seeing the machine learning trend turned into augmented reality, turned into virtual reality, turned into a weight. Actually, we should be using these for LLMs and AI. Like, having done all of that in his time since founding the company. Nobody, I don't think people should be second guessing. His instincts, his public statements scrutinizing his capital allocation. One of the big things is like, oh, Nvidia's like giving m

  View source ↗
• Newszacks.com·6d ago·Neutral

  Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know In the latest trading session, Johnson & Johnson (JNJ) closed at $267.66, marking a -1.58% move from the previous day.

  View source ↗
• Newsproactiveinvestors.com·6d ago·Negative

  Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says Johnson & Johnson (NYSE:JNJ)'s oral psoriasis drug Icotyde could reach $4.5 billion in peak sales, up from a previous $2.4 billion estimate, Bank of America said as it raised its price target on the company to $278 from $263. The broker now values estimated 2027 earnings excluding in-process research and development charges at 22 times, versus 20.33 previously, reflecting a sector rerating favoring defensive busi…

  View source ↗
• News (Marketaux)gurufocus.com·6d ago·Positive

  JNJ Maintains by JP Morgan -- Price Target Raised to $285 On October 05, 2023, JP Morgan maintaine[+232 characters]

  View source ↗
• News (RSS)seekingalpha·6d ago·Positive

  Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold

  View source ↗
• Newszacks.com·6d ago·Neutral

  Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

  View source ↗
• Newsseekingalpha.com·6d ago·Positive

  Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold On October 13, Johnson & Johnson will report its results for the third quarter. As a reminder, its Q2 revenue grew 6.6% year-over-year to $25.31 billion, primarily due to the strong performance of the multiple myeloma portfolio and Tremfya. On September 23, J&J said modeling projected nearly fourfold longer median overall survival with Tecvayli+Darzalex Faspro versus SoC in patients with R/R multiple myeloma.

  View source ↗
• Newsprnewswire.com·7d ago·Neutral

  …novel abstracts on IMAAVY to be presented at the MGFA Scientific Session during AANEM 2026 SPRING HOUSE, Pa., Sept. 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new findings on IMAAVY® (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting…

  View source ↗
• News247wallst.com·7d ago·Negative

  Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years Three stocks have raised their dividends for over 30 consecutive years through recessions, wars, and market crashes, and one has paid shareholders without interruption for 136 years straight.

  View source ↗
• News (RSS)zerohedge·7d ago·Neutral

  How The Data Center Debate May Shape The Midterms How The Data Center Debate May Shape The Midterms Authored by Jacki Thrapp via The Epoch Times, Outrage over proposed data centers surged across America, from the Birthplace of Rock 'n' Roll to Kansas corn country, amid a heated U.S. - China technology race, turning server farms into one of the defining issues of the midterm elections this fall. In some primaries, candidates who backed the artificial intelligence (AI) boom were given the boot by

  View source ↗
• News247wallst.com·7d ago·Negative

  Johnson & Johnson's Next Growth Engine Is Taking Shape Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull case or the headwinds win.

  View source ↗
• 4chan /biz/biz·8d ago·Neutral

  >>62732503 It's the most useless, crabby semi in existence. You're better off going with JNJ or JPM.

  View source ↗
• News (RSS)zerohedge·8d ago·Neutral

  Mamdani: Socialism "Will Absolutely Translate" Nationwide Mamdani: Socialism "Will Absolutely Translate" Nationwide Authored by Steve Watson via Modernity.news, New York City Mayor Zohran Mamdani has stopped pretending his socialist vision is just a local experiment. On CNN International's Amanpour, the Democratic Socialist was asked whether America is ready to elect people on the hard left - and whether the 2026 midterms will be a referendum not only on President Trump, but on the Democratic So

  View source ↗
• News247wallst.com·9d ago·Neutral

  Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really does repeat.

  View source ↗
• News (RSS)fool·10d ago·Positive

  AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

  View source ↗
• News (Marketaux)thestockmarketwatch.com·10d ago·Positive

  [DowJonesToday]Dow Jones Hits Record Highs as Cooling PCE Inflation Data Sparks Bullish Rally Healthcare stocks are also seeing signif[+299 characters]

  View source ↗
• Newsbenzinga.com·10d ago·Neutral

  Johnson & Johnson Clinical Trials Show Progress Across Key Therapies Johnson & Johnson (NYSE:JNJ) announced positive findings from key clinical evaluations testing its therapies, Tremfya and Carvykti, across psoriatic arthritis and multiple myeloma.

  View source ↗
• Newsproactiveinvestors.com·10d ago·Neutral

  Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 study. The company said Tremfya met the study's primary endpoint at week 24, showing greater improvement than placebo on a disease activity measure that includes spinal pain and stiffness.

  View source ↗
• Newsprnewswire.com·11d ago·Negative

  … confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA SPRING HOUSE, Pa., Sept. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in the Phase 4 STAR study evaluating biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA).

  View source ↗
• Newsprnewswire.com·11d ago·Negative

  …in second line, where earlier intervention may increase long-term remission and disease control RARITAN, N.J., Sept. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial subgroup of cohort A in the Phase 2 CARTITUDE-2 study (N=20) showing that 50% of patients (10/20) in early line relapsed or refractory multiple myeloma (RRMM) who were treated with a single infusion of CARVYKTI® (cil…

  View source ↗
• 4chan /biz/biz·11d ago·Neutral

  i'm going to tell you guys a great portfolio strategy it's a compounding strategy 6-10 tickers. No more. No less. I'll give you an 8 ticker sample. make BRKB and JNJ your anchors that's two already decided before you even start. They're there to be defensive, and smooth out the volatity of your portfolio. you may not like these because they're so low beta but you'll be glad you have them during corrections. your best hedge is your worst performing ticker during a bull market. That is your best…

  View source ↗
• News247wallst.com·11d ago·Positive

  Dave Ramsey Says You Need More Than 6% Just to Break Even. Dividend Growth Is One Way to Get There. A bond coupon that felt safe a decade ago may be quietly bleeding your retirement dry, and Dave Ramsey's hurdle-rate math explains exactly why. The question is which assets can actually climb that bar year after year.

  View source ↗
• News247wallst.com·11d ago·Neutral

  CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More When a retiree compares a federally insured CD to a dividend stock that has raised its payout for 70 straight years, the choice turns on a factor most income calculators ignore entirely.

  View source ↗
• Newsprnewswire.com·12d ago·Neutral

  …ed to deliver deeper, more durable disease control and improve long-term outcomes for patients  RARITAN, N.J., Sept. 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who had receive…

  View source ↗
• Newszacks.com·13d ago·Neutral

  JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

  View source ↗
• 4chan /biz/biz·14d ago·Neutral

  >>62710718 Are you the guy shilling it a couple of weeks back? The one that I asked why this instead of JNJ?

  View source ↗
• Newsreuters.com·14d ago·Negative

  J&J's Caplyta meets main goal of bipolar mania study Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal ​of a late-stage study, bringing the drug a step ‌closer to expanding beyond its currently approved uses.

  View source ↗
• News247wallst.com·16d ago·Positive

  3 Dividend Stocks Built for Retirement to Buy in September Retirement portfolios need income that shows up on time, grows faster than inflation, and does not blink during a downturn.

  View source ↗
• News (RSS)zerohedge·16d ago·Neutral

  Texas Daycare Faces Lawsuit For Running "Toddler Fight Club" Texas Daycare Faces Lawsuit For Running "Toddler Fight Club" Forget about Somali daycare fraud for a moment - have you heard about toddler fight club? A daycare in Fort Worth, TX is facing investigations and litigation after evidence showed staff abusing young children and forcing them to fight each other. One mother, Heather Harris, knew something was wrong when she picked up her 4-year-old son at the Arka Montessori Academy of Rising

  View source ↗
• News (Marketaux)thestockmarketwatch.com·17d ago·Negative

  [DowJonesToday]Dow Jones Retreats Amid Mixed Economic Signals and Tech Volatility In the technology space, Nvidia (NVDA) g[+276 characters]

  View source ↗
• News (Marketaux)thestockmarketwatch.com·17d ago·Neutral

  [DowJonesToday]Dow Jones Navigates Volatility Amid Shifting Economic Sentiment Other notable performers included Jo[+282 characters]

  View source ↗
• Newszacks.com·17d ago·Negative

  J&J Up 18% in Three Months: Buy, Sell or Hold the Stock? JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.

  View source ↗
• News (RSS)seekingalpha·18d ago·Positive

  Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

  View source ↗
• Newszacks.com·18d ago·Neutral

  Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know In the most recent trading session, Johnson & Johnson (JNJ) closed at $270.22, indicating a +1.1% shift from the previous trading day.

  View source ↗
• Newsseekingalpha.com·18d ago·Positive

  Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

  View source ↗
• Newsmarketbeat.com·18d ago·Positive

  Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff Johnson & Johnson NYSE: JNJ Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility.

  View source ↗
• News (RSS)zerohedge·19d ago·Negative

  Mysterious Illness Striking Young Workers In The South Mysterious Illness Striking Young Workers In The South Doctors at Harris County's public hospitals have spent more than a decade treating an unusual group of dialysis patients, men in their 20s and 30s who work outdoors and whose kidneys have failed without a clear medical explanation, Fox News reports, following a Texas Monthly investigation. A review of county hospital records found that roughly one in six emergency dialysis cases among un

  View source ↗
• News (Marketaux)thestockmarketwatch.com·19d ago·Positive

  [DowJonesToday]Dow Jones Slumps as Inflation Concerns Rattle Markets Tech giant Nvidia (NVDA) also showed res[+285 characters]

  View source ↗
• News (RSS)yahoo·19d ago·Neutral

  Gunnison Copper reaches deal with Nuton to expand Johnson Camp mine plan

  View source ↗
• News247wallst.com·19d ago·Positive

  Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year income plan.

  View source ↗
• Newsmarketbeat.com·20d ago·Neutral

  3 Healthcare Stocks for 3 Stages of Life When it comes to investing, there is no one-size-fits-all approach. Strategies vary based on numerous factors, including but not limited to investors' risk tolerance, net worth, and age.

  View source ↗
• Newsprnewswire.com·21d ago·Positive

  …benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib), with less frequent dosing and prophylactic strategies, can improve the treatment experience for patients with previously untreated advanced non-small cell l…

  View source ↗
• PodcastAll In·21d ago·Neutral

  [APPLAUSE] They don't listen to Johnson. But he's done an amazing job. And David has done an amazing job. Good luck to everybody. And we're going to stay with the future. The country has never done better. We have $20 trillion of investment coming into the country. And that's as opposed to much less than $1 trillion under Sleepy Joe Biden. And that was for four years. This isn't one year. It's really the country has never seen anything like it. And we're going to keep it going. And so thank you

  View source ↗
• News (RSS)seekingalpha·21d ago·Positive

  Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  View source ↗
• News (RSS)zerohedge·21d ago·Negative

  NATO Vows More Ukraine Support After Boris Johnson & David Petraeus Train Attack Near-Miss NATO Vows More Ukraine Support After Boris Johnson & David Petraeus Train Attack Near-Miss More escalation, NATO says. The Western military alliance's Secretary-General Mark Rutte said Monday that Russian drone strikes near the Ukraine-Poland border hit "close to NATO territory". He said the Sunday attack, which occurred merely hundreds of meters from Poland's border, smacked of Putin's "desperation and al

  View source ↗
• Newsreuters.com·21d ago·Negative

  Contineum, J&J's depression drug fails to meet mid-stage trial goal Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & ​Johnson failed to meet the main goal ‌of a mid-stage study.

  View source ↗
• Newsseekingalpha.com·21d ago·Positive

  Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  View source ↗
• News (RSS)yahoo·21d ago·Neutral

  Johnson & Johnson Shares Rise on Reported Apollo Talks for Orthopedics Unit

  View source ↗
• Newsmarketbeat.com·21d ago·Neutral

  Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition Johnson & Johnson NYSE: JNJ executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline programs to support accelerating growth through the end of the decade.

  View source ↗
• Newszacks.com·21d ago·Positive

  Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

  View source ↗
• News (RSS)zerohedge·21d ago·Neutral

  … single-stock perpetual futures in the US and is looking to expand the contracts in commodities to include agriculture. In deals, Apollo is in discussions to acquire Johnson & Johnson’s orthopedics unit for $20 billion, according to people familiar with the matter. Billionaire Michael Dell’s family office is nearing a deal to acquire The Baldwin Insurance Group, an insurance brokerage with a market value of $4.2 billion. Stock futures slide, led by tech names after leaders of the biggest artific…

  View source ↗
• News (RSS)aljazeera·22d ago·Negative

  Russia hits Ukrainian train shortly after Boris Johnson leaves station A Russian drone struck a train near Ukraine-Poland border, shortly after Former UK PM Boris Johnson left the station.

  View source ↗
• Newsglobenewswire.com·22d ago·Negative

  NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable…

  View source ↗
• News (Marketaux)acquirersmultiple.com·22d ago·Positive

  Jeremy Grantham’s Latest Portfolio: Top 10 Holdings & Biggest Trades Top 10 Holdings & Weights Microsoft Cor[+353 characters]

  View source ↗
• News (RSS)zerohedge·22d ago·Neutral

  Johnson Says $5,000 Trump Payments Require Congress To Act Johnson Says $5,000 Trump Payments Require Congress To Act House Speaker Mike Johnson (R-LA) said on Sunday that President Trump's plan to send $5,000 dividend checks to American adults if Republicans keep both the House and Senate would require an act of Congress. House Speaker Mike Johnson (R-La.) speaks during the second day of the 2026 Republican Midterm Convention in Dallas on Sept. 10, 2026. Madalina Kilroy/The Epoch Times "I would

  View source ↗
• Newsprnewswire.com·22d ago·Positive

  …patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor rece…

  View source ↗
• 4chan /biz/biz·22d ago·Negative

  >>62686295 I mentioned the divvies as a safety net, worst case when NVO crabs, I get decent dividends. Also, analyst targets are better for NVO (9.658% to go to 1yr target) than JNJ (4.642% to go to 1yr target) I'm telling you, and the analysts agree, JNJ already ran, and has 3x the P/E ratio of NVO.

  View source ↗
• News (Marketaux)finance.yahoo.com·22d ago·Positive

  Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance. Temporary shipping disruption can hand p[+316 characters]

  View source ↗
• 4chan /biz/biz·22d ago·Positive

  >>62686289 You said you're alright with just the divvies in your first post, that's why I assumed JNJ is a better buy. Regardless, I'm gonna trust the analysts over a random frogposter.

  View source ↗
• 4chan /biz/biz·22d ago·Neutral

  >>62686279 >buying the news Oh no no See I'm kinda decent at catching falling knives. JNJ is already frontran. Unless they do a MRNA and come out with a cure for cancer, they aren't going much further up. NVO on the other hand is fudded to hell just because their fat loss product is slightly worse than Lilly's. These fat loss pills will just keep getting better with less side effects and people will put more trust on known brands intead of buying Indian generics. Only a matter of time before NVO…

  View source ↗
• 4chan /biz/biz·22d ago·Neutral

  >>62686266 Because the news are bullish for JNJ and bearish for NVO?

  View source ↗
• 4chan /biz/biz·22d ago·Positive

  >>62686228 JNJ is near its ATH without any major pullbacks and a 30 P/E. Why would I buy the top when there's a pharma behemoth elsewhere at a discount?

  View source ↗
• 4chan /biz/biz·22d ago·Neutral

  >>62686179 NVO doesn't look too attractive. Why not JNJ instead?

  View source ↗
• News (Marketaux)cnbc.com·22d ago·Positive

  Here are the 2 big things we're watching in this week's stock market Cardinal Health , Johnson & <em[+266 characters]

  View source ↗
• News (RSS)seekingalpha·22d ago·Neutral

  Johnson urges caution on AI legislation as tech chiefs call for safeguards

  View source ↗
• News (RSS)zerohedge·22d ago·Neutral

  "Something's Going To Happen": DHS Chief Says Lefty Ilhan Omar "Married Her Brother", Floats Deportation "Something's Going To Happen": DHS Chief Says Lefty Ilhan Omar "Married Her Brother", Floats Deportation Homeland Security Secretary Markwayne Mullin said "something's going to happen" in an ongoing investigation involving unhinged leftist Rep. Ilhan Omar (D-Minn.), speaking with conservative podcaster Benny Johnson at the GOP midterm convention in Dallas. Mullin said that Omar married her br

  View source ↗
• Newswsj.com·23d ago·Negative

  J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion The health-products company said it planned to hive off its DePuy Synthes unit to focus on higher-growth areas.

  View source ↗
• News (RSS)zerohedge·23d ago·Negative

  … in the United States over alleged risks associated with prenatal exposure. Texas Attorney General Ken Paxton has sued Kenvue, which now owns the Tylenol brand after Johnson & Johnson spun off its consumer health business into a new company in 2023. The suit alleged that the company engaged in deceptive advertising by failing to disclose evidence concerning a possible link between prenatal Tylenol exposure and autism. While a judge dismissed most of the claims, one consumer-protection claim agai…

  View source ↗
• News247wallst.com·24d ago·Neutral

  How Much Do You Really Need Invested in Dividend Stocks to Replace a $25,000 Income? The math behind living off dividends exposes a brutal tradeoff: every percentage point of extra yield you chase to shrink your required capital brings a hidden cost that most income investors never price in before sizing their positions.

  View source ↗
• Newsfool.com·24d ago·Positive

  2 Outstanding Dividend Stocks to Buy and Hold for 10 Years Income seekers can't go wrong with these companies.

  View source ↗
• News (Marketaux)thestockmarketwatch.com·24d ago·Positive

  [DowJonesToday]Dow Jones Surges as Industrial Strength Offsets Tech Volatility Other notable gainers included Nvidia (N[+309 characters]

  View source ↗
• News (RSS)zerohedge·24d ago·Neutral

  Futures Rise As Oil Prices Drop Ahead Of CPI Report Futures Rise As Oil Prices Drop Ahead Of CPI Report Futures are higher thanks to an overnight retreat in oil prices (which is unlikely to hold now that Houthi rebels effectively control the entire Red Sea) and bond yields which track oil tick for tick, but the tone could quickly shift with the week’s biggest catalyst, August CPI data, due before the cash open. As of 8:00am ET, S&P and Nasdaq futures gain 0.6% with Mag 7 stocks are mostly higher

  View source ↗
• Newszacks.com·24d ago·Positive

  3 Top Dividend Aristocrats To Own Near All-Time Highs Several Dividend Aristocrats, including Johnson & Johnson (JNJ), Coca-Cola (KO), and Exxon Mobil (XOM), are trading near all-time highs, reflecting bullish momentum driven by strong results or favorable operating conditions.

  View source ↗
• News (Marketaux)thestockmarketwatch.com·25d ago·Positive

  [DowJonesToday]Dow Jones Slumps as Hot Inflation Data Dampens Rate Cut Hopes Defensive healthcare also saw inflows; <[+284 characters]

  View source ↗
• News (Marketaux)thestockmarketwatch.com·26d ago·Neutral

  [DowJonesToday]Dow Jones Slumps as Inflation Concerns Weigh on Market Sentiment Technology and healthcare also showed po[+263 characters]

  View source ↗